Incidence of Cancer-Associated Venous Thromboembolism in Patients With Solid Cancers in Japan ― A Prospective Study ―
Abstract
BACKGROUND: Data on asymptomatic deep vein thrombosis (DVT) remain limited. This prospective study investigated the incidence of cancer-associated venous thromboembolism (CA-VTE) in patients receiving cancer treatment with scheduled DVT monitoring. METHODS AND RESULTS: Patients with newly diagnosed locally advanced, recurrent, or metastatic solid cancers without prior VTE were enrolled. Mandatory baseline venous ultrasonography excluded pre-existing DVT. VTE was assessed at Weeks 12, 24, 36, 48, 72, and 96 by lower-extremity ultrasonography, supplemented by contrast-enhanced computed tomography. The primary endpoint was the incidence of CA-VTE within 24 weeks, and a key secondary endpoint was the incidence within 96 weeks. Cox proportional hazards regression was used to explore factors predictive of newly developed VTE. Among 178 patients (median age 68 years; 32% female), the most common primary site of cancer was the gastrointestinal tract (38%). Adenocarcinoma and squamous cell carcinoma each accounted for 43% of enrolled cases. VTE occurred in 23 (12.9%) and 36 (20.2%) patients within 24 and 96 weeks, with most being asymptomatic (91.3% and 69.4%, respectively). CA-VTE incidence did not differ by tumor site or histology, and no predictive factors were identified. Eleven patients required anticoagulation at VTE diagnosis, and 3 further patients required anticoagulation after progression of initially asymptomatic distal DVT. CONCLUSIONS: CA-VTE incidence was alarmingly high, regardless of tumor site or histology. Because anticoagulation was required in a considerable proportion of patients who developed VTE, scheduled DVT monitoring may be warranted.
Related
- Incidence of venous thromboembolism with intraoperative tranexamic acid use in breast surgery patients on estrogen-containing medications: a case series
- Incidence, risk factors and prognostic impact of venous thromboembolism in patients with advanced non-small cell lung cancer receiving systemic therapy: a single-center retrospective analysis.
- Incidence and Progression of Acute Kidney Injury Following Head and Neck Surgeries for COVID-19-Associated Mucormycosis: A Prospective Observational Study
- Early Adverse Neonatal Outcomes Among Women With Diabetes in Pregnancy in Uganda: Incidence, Distribution and Associated Factors in a Multicenter Prospective Cohort Study
- Quality of Life and Patient-Reported Outcomes During First-Line Chemotherapy in Older Patients with De Novo Metastatic Gastrointestinal Cancers: A Prospective Longitudinal Study.
BibTeX
@article{ohata2026incidence,
title = {{Incidence of Cancer-Associated Venous Thromboembolism in Patients With Solid Cancers in Japan ― A Prospective Study ―}},
author = {Shinya Ohata and Yoshinori Imamura and Taku Nose and Kenta Mori and Kazunori Otsui and Takumi Imai and Shiro Kimbara and Yoshiaki Nagatani and Taiji Koyama and Yohei Funakoshi and Naomi Kiyota and Hironobu Minami},
journal = {Circulation Journal},
year = {2026},
month = aug,
doi = {10.1253/circj.cj-26-0016},
url = {https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0016/_article},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Incidence of Cancer-Associated Venous Thromboembolism in Patients With Solid Cancers in Japan ― A Prospective Study ―
AU - Shinya Ohata
AU - Yoshinori Imamura
AU - Taku Nose
AU - Kenta Mori
AU - Kazunori Otsui
AU - Takumi Imai
AU - Shiro Kimbara
AU - Yoshiaki Nagatani
AU - Taiji Koyama
AU - Yohei Funakoshi
AU - Naomi Kiyota
AU - Hironobu Minami
PY - 2026
DA - 2026/08/20
JO - Circulation Journal
DO - 10.1253/circj.cj-26-0016
UR - https://www.jstage.jst.go.jp/article/circj/advpub/0/advpub_CJ-26-0016/_article
AB - BACKGROUND: Data on asymptomatic deep vein thrombosis (DVT) remain limited. This prospective study investigated the incidence of cancer-associated venous thromboembolism (CA-VTE) in patients receiving cancer treatment with scheduled DVT monitoring. METHODS AND RESULTS: Patients with newly diagnosed locally advanced, recurrent, or metastatic solid cancers without prior VTE were enrolled. Mandatory baseline venous ultrasonography excluded pre-existing DVT. VTE was assessed at Weeks 12, 24, 36, 48, 72, and 96 by lower-extremity ultrasonography, supplemented by contrast-enhanced computed tomography. The primary endpoint was the incidence of CA-VTE within 24 weeks, and a key secondary endpoint was the incidence within 96 weeks. Cox proportional hazards regression was used to explore factors predictive of newly developed VTE. Among 178 patients (median age 68 years; 32% female), the most common primary site of cancer was the gastrointestinal tract (38%). Adenocarcinoma and squamous cell carcinoma each accounted for 43% of enrolled cases. VTE occurred in 23 (12.9%) and 36 (20.2%) patients within 24 and 96 weeks, with most being asymptomatic (91.3% and 69.4%, respectively). CA-VTE incidence did not differ by tumor site or histology, and no predictive factors were identified. Eleven patients required anticoagulation at VTE diagnosis, and 3 further patients required anticoagulation after progression of initially asymptomatic distal DVT. CONCLUSIONS: CA-VTE incidence was alarmingly high, regardless of tumor site or histology. Because anticoagulation was required in a considerable proportion of patients who developed VTE, scheduled DVT monitoring may be warranted.
SN - 1347-4820
SN - 1346-9843
ER -